Terbogrel (INN[1]) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor.[2][3] The drug was developed by Boehringer Ingelheim.
Names | |
---|---|
IUPAC name
(5E)-6-{3-[tert-Butyl(cyano)carbamimidamido]phenyl}-6-pyridin-3-ylhex-5-enoic acid
| |
Other names
(5E)-6-[m-(3-tert-Butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
KEGG |
|
PubChem CID
|
|
UNII |
|
| |
| |
Properties | |
C23H27N5O2 | |
Molar mass | 405.502 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|
A phase 2 clinical trial of terbogrel was discontinued due to its induction of leg pain.[4]